Citigroup Inc. (NYSE:C) popped in on a high volume green day. Volume on 28-Nov-17 came in at 17.87 million contracts. The daily trading volume has averaged 14.56 million shares a day in past 3 months. The first sale was made at $71.44 but later the stock became weaker, and closed with a gain of 3.24%. It was last traded at $73.7 apiece. Citigroup Inc. is maintained at an average outperform rating by 31 stock analysts, and there are at least 0.98% of shares outstanding that are currently legally short sold. The shares went down by -0.23% in value last month. Year-to-date it jumped 24.01%. Analysts are turning out to be more optimistic than before, with 18 of analysts who cover Citigroup Inc. (NYSE:C) advice adding it to buy candidate list. Wall Street experts also assign a $76.47 price target on Citigroup Inc., pointing towards a 3.76% rally from current levels. The stock is trading for about -3.2% less than its 52-week high. Citigroup Inc. (C) remained successful in beating the consensus-estimated $1.33 as it actually earned $1.42 per share in its last reported financial results. Revenue, on the other hand, scored -0.03% growth from the previous quarter, coming up with $17.9 billion.  This company shares (C) so far managed to recover 33.44% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 1.62% while shortening the period to a week, volatility was 1.46%. The share price has already crossed its 20 days moving average, floating at a distance of 1.52% and sits 1.13% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 2.29% gains and is up by 12.21% compared with its 200-day moving average of $68.32. Also, Citigroup Inc. (C) needs to expand a 32.86% increase it experienced over the past twelve months. As regular trading ended, Eyegate Pharmaceuticals, Inc. (EYEG) stock brought in a $0.04 rise to $1.1. The day started at a price of $1.01 but then traded as high as $1.11 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2. Eyegate Pharmaceuticals, Inc. is given 0 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -71.8% from their peak of $3.90 and now has a $18.74 million market value of equity. EYEG’s mean recommendation on Reuter’s scale presents no change from 2 thirty days ago to 2 now, which indicates a hold consensus from the analyst community. They see Eyegate Pharmaceuticals, Inc. (EYEG) price hitting a mean target of $6.33 a share, meaning the stock still has potential that could lift the price another 475.45% Also, the recent close suggests the stock is underpriced by 354.55% compared to the most bullish target. The company had seen its current volume reaching at 0.29 million shares in the last trade. That compares with the recent volume average of 0.21 million. At the close of regular trading, its last week’s stock price volatility was 6.6% which for the month reaches 5.44%. Eyegate Pharmaceuticals, Inc. dipped to as low as $1.01 throughout the day and has returned -32.52% in this year. At one point in the past year, the shares traded as low as $0.90 but has recovered 22.21% since then.